Navigation Links
BioMarCare Technologies Ltd. Receives a $900k Grant for a Joint Project with Ariadne Inc.
Date:8/2/2011

NEW YORK, Aug. 2, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, and its subsidiary, BioMarCare Technologies Ltd. ("BioMarCare") announced that the prestigious Binational Industrial Research and Development (BIRD) Foundation has given initial approval for a $900,000 grant for a joint project for BioMarCare and Ariadne Inc. to develop a diagnostic colorectal cancer test.

BioMarCare and Ariadne Inc. will jointly develop a diagnostic test, based on a panel of protein biomarkers, to direct the personal care of patients with metastatic stage colorectal cancer. Current treatments for metastatic colorectal cancer are ineffective for a significant percentage of patients treated and the new test would enable physicians to detect the non-responders prior to treatment.  This would allow for a more effective course of treatment to be administered at an earlier stage of the disease, which is in line with the current medical trend towards more efficient personalized medicine.

Colorectal cancer is the third most common malignant disease worldwide, with more than one million new cases discovered annually and more than 30% diagnosed with metastatic stage cancer.

In addition to this important project, BioMarCare is also in the processes of developing diagnostic tools for colon cancer and breast cancer that are based on a simple blood test. These tests utilize proprietary biomarkers, licensed from the Hadassah Medical Organization's technology transfer company- Hadasit, and have shown high sensitivity even at early stages of the disease.

The BIRD grant is one of 9 grants approved for Israeli American collaborations in 2011, and is granted to Israeli and American collaborations in various fields, not only medical. The grant will be matched by company funds and will be repaid through royalty payments from the developed product. BioMarCare and Ariadne Inc. are currently finalizing their collaboration agreement and will then finalize an agreement with the BIRD Foundation, as required by the fund.

BioMarCare's CEO, Dana Cohen, said, "The prestigious BIRD Foundation's grant enables the Company to develop a diagnostic product which will reduce ineffective treatment of patients and excessive costs to the healthcare system. Product development with Ariadne Inc. will also extend the Company's reach to the U.S. market and may be the basis for developing additional tests to guide treatment of cancer in the future."

About Hadasit Bio-Holdings

Hadasit Bio-Holdings Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center.  The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.

HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle representing a portfolio of biotech companies, all based on inventions developed at Hadassah.  

Hadasit Bio-Holdings focuses on advancing companies that are past successful preclinical trials and close to completion of Phase I/II clinical trials. The portfolio companies develop drugs with blockbuster potential (markets that are worth over a billion dollars) and operate in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader.

For more information please visit: www.hbl.co.il

Investor Contact
KCSA Strategic Communications
Jeff Corbin / Rob Fink
jcorbin@kcsa.com / rfink@kcsa.com
(212) 896-1206


'/>"/>
SOURCE Hadasit Bio-Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
Breaking Medicine News(10 mins):